Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTLF FitLife Brands	$13.64 -5.7%	$13.46	$9.83 ▼ $17.75	$128.00M	0.9	18,266 shs	30,155 shs
NKTX Nkarta	$1.74 +1.2%	$1.79	$1.31 ▼ $8.23	$123.47M	0.81	1.07 million shs	591,174 shs
RVPH Reviva Pharmaceuticals	$0.82 -2.3%	$0.84	$0.49 ▼ $4.28	$38.33M	0.08	1.14 million shs	464,744 shs
SLS SELLAS Life Sciences Group	$1.63 +1.9%	$1.30	$0.77 ▼ $1.85	$154.11M	2.34	1.43 million shs	2.78 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTLF FitLife Brands	0.00%	-12.51%	+2.25%	-9.97%	-7.93%
NKTX Nkarta	0.00%	-10.54%	-3.87%	-21.27%	-74.71%
RVPH Reviva Pharmaceuticals	0.00%	+0.04%	+4.81%	-54.44%	-52.05%
SLS SELLAS Life Sciences Group	0.00%	+4.49%	+25.38%	+23.48%	+10.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FTLF FitLife Brands	4.5016 of 5 stars	3.7	5.0	2.3	3.3	3.1
NKTX Nkarta	2.0731 of 5 stars	3.6	1.0	2.6	1.7	0.6
RVPH Reviva Pharmaceuticals	3.046 of 5 stars	3.6	2.0	3.2	3.3	0.6
SLS SELLAS Life Sciences Group	0.9072 of 5 stars	0.0	4.0	3.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTLF FitLife Brands	3.33	Buy	$20.50	50.29% Upside
NKTX Nkarta	3.13	Buy	$14.67	742.91% Upside
RVPH Reviva Pharmaceuticals	3.29	Buy	$10.00	1,119.51% Upside
SLS SELLAS Life Sciences Group	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RVPH, SLS, FTLF, and NKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
4/24/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/9/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/1/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.00
3/27/2025	NKTX Nkarta	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
3/27/2025	NKTX Nkarta	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/27/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/17/2025	FTLF FitLife Brands	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTLF FitLife Brands	$64.47M	1.99	$0.72 per share	19.05	$3.04 per share	4.49
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.56 per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.20 per share	N/A
SLS SELLAS Life Sciences Group	$1M	154.11	N/A	N/A	($0.25) per share	-6.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTLF FitLife Brands	$5.30M	$0.84	16.14	12.40	N/A	13.38%	28.03%	15.13%	N/A
NKTX Nkarta	-$117.50M	-$1.66	N/A	N/A	N/A	N/A	-27.13%	-21.67%	N/A
RVPH Reviva Pharmaceuticals	-$39.26M	-$0.91	N/A	N/A	N/A	N/A	N/A	-252.53%	N/A
SLS SELLAS Life Sciences Group	-$37.34M	-$0.38	N/A	N/A	N/A	N/A	-629.46%	-178.65%	N/A

Latest RVPH, SLS, FTLF, and NKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	FTLF FitLife Brands	$0.24	$0.20	-$0.04	$0.20	N/A	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/13/2025	Q1 2025	RVPH Reviva Pharmaceuticals	-$0.21	-$0.13	+$0.08	-$0.13	N/A	N/A
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
3/31/2025	Q4 2024	RVPH Reviva Pharmaceuticals	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
3/27/2025	Q4 2024	FTLF FitLife Brands	$0.22	$0.21	-$0.01	N/A	N/A	N/A
3/26/2025	Q4 2024	NKTX Nkarta	-$0.41	-$0.35	+$0.06	-$0.35	N/A	N/A
3/20/2025	Q4 2024	SLS SELLAS Life Sciences Group	-$0.1067	-$0.08	+$0.0267	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTLF FitLife Brands	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTLF FitLife Brands	0.28	1.50	0.64
NKTX Nkarta	N/A	12.91	12.91
RVPH Reviva Pharmaceuticals	N/A	0.39	0.39
SLS SELLAS Life Sciences Group	N/A	2.26	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTLF FitLife Brands	2.32%
NKTX Nkarta	80.54%
RVPH Reviva Pharmaceuticals	63.18%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
FTLF FitLife Brands	61.30%
NKTX Nkarta	8.70%
RVPH Reviva Pharmaceuticals	27.18%
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTLF FitLife Brands	20	9.38 million	3.56 million	Not Optionable
NKTX Nkarta	140	70.96 million	64.43 million	Optionable
RVPH Reviva Pharmaceuticals	5	46.74 million	24.35 million	Optionable
SLS SELLAS Life Sciences Group	10	94.55 million	69.54 million	Not Optionable

RVPH, SLS, FTLF, and NKTX Headlines

Recent News About These Companies

SELLAS Life Sciences Group, Inc. Common Stock

May 16 at 9:09 PM | fxempire.com

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

May 16 at 9:09 PM | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15 at 3:35 PM | finanznachrichten.de

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15 at 8:45 AM | globenewswire.com

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025 | globenewswire.com

SELLAS Life Sciences Group (SLS) Projected to Post Earnings on Tuesday

May 11, 2025 | americanbankingnews.com

SELLAS Life Sciences Group (SLS) to Release Earnings on Tuesday

May 8, 2025 | marketbeat.com

Anson Funds Management LP Has $1.24 Million Holdings in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

May 5, 2025 | marketbeat.com

SELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025

April 28, 2025 | quiverquant.com

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

April 28, 2025 | globenewswire.com

Why SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Up 8.95%

April 26, 2025 | aaii.com

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher - Time to Buy?

April 26, 2025 | marketbeat.com

SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting

April 23, 2025 | quiverquant.com

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025 | globenewswire.com

Sellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trial

April 9, 2025 | markets.businessinsider.com

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

April 8, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock (SLS) Insider Activity

March 30, 2025 | nasdaq.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

March 21, 2025 | finanznachrichten.de

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

March 20, 2025 | globenewswire.com

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment

February 21, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

February 20, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH, SLS, FTLF, and NKTX Company Descriptions

FitLife Brands NASDAQ:FTLF

$13.64 -0.82 (-5.67%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$13.72 +0.07 (+0.55%)

As of 05/16/2025 04:46 PM Eastern

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Nkarta NASDAQ:NKTX

$1.74 +0.02 (+1.16%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$1.75 +0.01 (+0.63%)

As of 05/16/2025 07:36 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.82 -0.02 (-2.26%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$0.83 +0.01 (+0.73%)

As of 05/16/2025 07:16 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

SELLAS Life Sciences Group NASDAQ:SLS

$1.63 +0.03 (+1.88%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$1.62 0.00 (-0.31%)

As of 05/16/2025 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time